HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Grattan, M. T. Articles by Shumway, N. E. Search for Related Content PubMed PubMed Citation Articles by Grattan, M. T. Articles by Shumway, N. E.

The Journal of Thoracic and Cardiovascular Surgery, Vol 99, 500-509, Copyright © 1990 by The American Association for Thoracic Surgery and The Western Thoracic Surgical Association

ARTICLES

Eight-year results of cyclosporine-treated patients with cardiac transplants

MT Grattan, CE Moreno-Cabral, VA Starnes, PE Oyer, EB Stinson and NE Shumway
Department of Cardiovascular Surgery, Stanford University Medical Center, Calif.

To elucidate the long-term effects of cyclosporine, we retrospectively studied 310 consecutive patients who have undergone cardiac transplantation at our institution since December 1980 and in whom immunosuppression has been maintained with cyclosporine. The ages of recipients ranged from 1 month to 64 years and of donors from 1 month to 48 years. The actuarial survival rates for cyclosporine-treated patients were 80.7% at 1 year and 59.7% at 5 years and were significantly greater than those for previous patients not treated with cyclosporine (p less than 0.005). Their actuarial prevalence of rejection was 60.0% at 1 month and 86.9% at 1 year; 206 patients are living. The actuarial prevalence of lymphoma development was 4.6% at 5 years but has been significantly lower with the current immunosuppression protocol of lower doses of cyclosporine, and OKT3 in place of rabbit anti-thymocyte globulin (p less than 0.005). Infection remains the most common cause of death. Recipients less than 50 years of age had a significantly higher actuarial survival than older recipients (p less than 0.01). Male and female recipients had similar overall prevalence of survival and rejection, but men died of graft atherosclerosis significantly more frequently (p less than 0.005). Rehabilitation has been successful in 85% of patients surviving 1 year after transplantation. Of those surviving 1 year, 96.5% were in New York Heart Association class I. Thus the results of orthotopic cardiac transplantation have improved since the introduction of cyclosporine and have allowed measured liberalization of the criteria for recipient selection.

This article has been cited by other articles:

				I. M. Hamour, A. Khaghani, P. K. Kanagala, A. G. Mitchell, and N. R. Banner Current outcome of heart transplantation: a 10-year single centre perspective and review QJM, April 1, 2011; 104(4): 335 - 343. [Abstract] [Full Text] [PDF]

				Y. S. Tjang, G. J.M.G. van der Heijden, G. Tenderich, R. Korfer, and D. E. Grobbee Impact of Recipient's Age on Heart Transplantation Outcome Ann. Thorac. Surg., June 1, 2008; 85(6): 2051 - 2055. [Abstract] [Full Text] [PDF]

				R. L. Page II, G. G. Miller, and J. Lindenfeld Drug Therapy in the Heart Transplant Recipient: Part IV: Drug-Drug Interactions Circulation, January 18, 2005; 111(2): 230 - 239. [Full Text] [PDF]

				C. Isnard Bagnis, S. Tezenas du Montcel, H. Beaufils, C. Jouanneau, M. C. Jaudon, P. Maksud, A. Mallet, P. LeHoang, and G. Deray Long-Term Renal Effects of Low-Dose Cyclosporine in Uveitis-Treated Patients: Follow-Up Study J. Am. Soc. Nephrol., December 1, 2002; 13(12): 2962 - 2968. [Abstract] [Full Text] [PDF]

				R. John, H. A. Rajasinghe, S. Itescu, S. Suratwalla, K. Lietz, A. D. Weinberg, A. Kocher, D. M. Mancini, R. E. Drusin, M. C. Oz, et al. Factors affecting long-term survival (>10 years) after cardiac transplantation in the cyclosporine era J. Am. Coll. Cardiol., January 1, 2001; 37(1): 189 - 194. [Abstract] [Full Text] [PDF]

				R. C. Robbins, C. W. Barlow, P. E. Oyer, S. A. Hunt, J. L. Miller, B. A. Reitz, E. B. Stinson, and N. E. Shumway THIRTY YEARS OF CARDIAC TRANSPLANTATION AT STANFORD UNIVERSITY J. Thorac. Cardiovasc. Surg., May 1, 1999; 117(5): 939 - 951. [Abstract] [Full Text] [PDF]

				W. M. DeCampli, H. Luikart, S. Hunt, and E. B. Stinson Characteristics of patients surviving more than ten years aftercardiac transplantation J. Thorac. Cardiovasc. Surg., June 1, 1995; 109(6): 1103 - 1115. [Abstract] [Full Text]

				B. Hausen, S. Demertzis, R. Rohde, J. M. Albes, H.-J. Schafers, and H.-G. Borst Low-dose cyclosporine therapy in triple-drug immunosuppression for heart transplant recipients Ann. Thorac. Surg., October 1, 1994; 58(4): 999 - 1004. [Abstract] [PDF]

				G. E. Sarris, K. A. Moore, J. S. Schroeder, S. A. Hunt, M. B. Fowler, H. B. Valantine, R. H. Vagelos, M. E. Billingham, P. E. Oyer, E. B. Stinson, et al. Cardiac transplantation: The Stanford experience in the cyclosporine era J. Thorac. Cardiovasc. Surg., August 1, 1994; 108(2): 240 - 252. [Abstract] [Full Text]

				U. Livi, G. B. Luciani, G. M. Boffa, G. Faggian, U. Bortolotti, G. Thiene, and A. Mazzucco Clinical results of steroid-free induction immunosuppression after heart transplantation Ann. Thorac. Surg., May 1, 1993; 55(5): 1160 - 1165. [Abstract] [PDF]